DV Biologics, System Biosciences Ink Stem Cell Partnership | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DV Biologics and System Biosciences this week announced a partnership to develop human-derived, disease-specific induced pluripotent stem cell lines.

Under the terms of the deal, System Biosciences will convert many of DV Biologics' disease-specific cell types into iPSCs, using its proprietary products for reprogramming and iPSC generation, the two firms said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.